Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06145724 · ClinicalTrials.gov registry record · NA

EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)

A NA study of Infections and Maternal Sepsis, sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
33,183
Enrollment target
4
Study locations

NCT06145724: Recruiting NA study of Infections and Maternal Sepsis, sponsored by Columbia University.

NCT06145724 is a NA study of Infections and Maternal Sepsis that is actively recruiting participants, run by Columbia University. The registered enrollment target is 33,183 participants, above the 2,131-participant average among 26 other Infections trials with a reported enrollment target (1457% higher). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06145724, a NA study of Infections and Maternal Sepsis, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
33,183 participants
Enrollment target
4
Study locations

Study Summary

Sepsis is the second leading cause of maternal death in the U.S. Labor and postpartum are particularly vulnerable risk periods. The goal of this multi-center, multidisciplinary study is to evaluate a maternal sepsis safety bundle.

Primary Outcome

The number of patients diagnosed with maternal sepsis pre- and post- material sepsis bundle implementation. Sepsis as evaluated by the following scoring systems: Sepsis-2 (proven or suspected infection in combination with at least two systemic inflammatory response syndrome criteria); Sepsis-3 (organ dysfunction as defined by an acute change in total organ dysfunction score within 24 hours of suspected infection); and Center for Disease Control (CDC) Sepsis (presumed infection and organ dysfunct

Interventions

  • BEHAVIORAL Maternal Sepsis Safety Bundle

Study Locations (4)

New York

  • Columbia Unviersity Irving Medical Center - New York
  • NewYork-Presbyterian Allen Hospital - New York
  • NYC Health+Hospitals/Harlem - New York
  • NYC Health + Hospitals/Lincoln - The Bronx

Trial Details

FieldValue
Enrollment Target 33,183 participants
Start Date 2025-06-01
Est. Completion 2026-09-20
Phase NA
Columbia University

958 total trials

What NCT06145724 shows while recruiting

NCT06145724 is an interventional study that assigns participants to a tested intervention. Its 33,183 participants enrollment target places it among the larger protocols in the corpus, above the 2,131-participant average among 26 other Infections trials with a reported enrollment target (1457% higher).

The record links to 2 conditions, with Infections appearing as the primary indexed condition, and to 1 intervention - of which Maternal Sepsis Safety Bundle is the first listed.

NCT06145724 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06145724 about?

NCT06145724 is a clinical study titled "EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)". Sepsis is the second leading cause of maternal death in the U.S. Labor and postpartum are particularly vulnerable risk periods. The goal of this multi-center, multidisciplinary study is to evaluate a maternal sepsis safety bundle.

What is the current status of trial NCT06145724?

This trial is currently recruiting. It is a NA study. The enrollment target is 33,183 participants. The study started on 2025-06-01. Estimated completion is 2026-09-20.

What conditions does trial NCT06145724 study?

This clinical trial studies the following conditions: Infections, Maternal Sepsis.

What interventions are being tested in trial NCT06145724?

The interventions under investigation include: Maternal Sepsis Safety Bundle (BEHAVIORAL).

Who is sponsoring clinical trial NCT06145724?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06145724 being conducted?

This trial has 4 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06145724's enrollment target sits among peer trials

33,183 1st of 26 higher than 26 of 26 other Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04477928 · 33,000 participants

    General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

  • NCT07282665 · 32,000 participants · Phase 3

    A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

  • NCT03720613 · 34,532 participants

    Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

  • NCT02225301 · 35,000 participants · NA

    iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06145724, the US trial registry maintained by the National Library of Medicine. NCT06145724 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.